FLT3 and acute myeloid leukemia: NPM1‐mutated AML accounts for more than 50% of normal karyotype AML and while the individual impact of MRD, disease status, and FLT3‐ITD has been investigated, little is known about their combined respective contributions in influencing posttransplant outcome.5, 7